Novo Nordisk's stock surged 25% in the past month, recovering from multi-year lows due to the launch of oral versions of its Ozempic and Wegovy weight loss drugs, FDA approvals, and telehealth partnerships. The company also slightly raised its sales guidance, signaling confidence in its restructuring efforts. With relatively low market valuations, the stock remains a buy as these positive developments suggest growth potential ahead.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
